Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

William H. Yong, M.D.
William H. Yong, M.D.



General Information:



Professor, Department of Pathology and Laboratory Medicine
Member, Brain Research Institute
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Neuropathology, UCLA School of Medicine, 1995 - 1998
Anatomic and Clinical Pathology, Massachusetts General Hospital, 1991 - 1995
Medical Degree:
M.D., UCLA School of Medicine, 1991
M.A., Biology (Cell and Molecular), San Francisco State University, 1987
B.A., Molecular Biology, UC Berkeley, 1984


Board Certification(s):
Anatomic Pathology, American Board of Pathology, 1999
Neuropathology, American Board of Pathology, 1999

Practice Information:

Clinical Interest(s):
Brain Tumors
Pituitary Tumors and Lesions
Epilepsy Pathology
Neuromuscular Pathology

Scientific Interest(s):

The overarching goal of Dr. William Yong’s lab is to improve the delivery and quality of neuropathology diagnoses, ultimately enhancing the ability of patients and clinicians to make better therapy decisions more quickly. They study biomarkers in surgical and autopsy brain tumor tissues to predict response to therapy. In close cooperation with others in the UCLA Brain Tumor program, Yong’s lab hopes to translate these findings into individualized treatment profiles for each brain tumor patient by amalgamating biomarker results with the standard histopathologic diagnoses in pathology reports. His lab integrates multiple approaches including information technology, histopathology, digital imaging, and molecular genetic tools.

Selected Cancer-Related Publications:

Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009 Apr;27(4):980-7.

Lasky JL, Choi EJ, Johnston S, Yong WH, Lazareff J, Moore T. Congenital brain tumors: case series and review of the literature. J Pediatr Hematol Oncol. 2008 Apr;30(4):326-31.

Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel PS. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15;14(2):488-93.

Lelievre V, Seksenyan A, Nobuta H, Yong WH, Chhith S, Niewiadomski P, Cohen JR, Dong H, Flores A, Liau LM, Kornblum HI, Scott MP, Waschek JA. Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Dev Biol. 2008 Jan 1;313(1):359-70. Epub 2007 Nov 26.

Yong WH, Butte PV, Pikul BK, Jo JA, Fang Q, Papaioannou T, Black K, Marcu L. Distinction of brain tissue, low grade and high grade glioma with time-resolved fluorescence spectroscopy. Front Biosci. 2006 May 1;11:1255-63.